Alterations in tumour or T cell phenotype were measured by flow cytometry or immunofluorescent microscopy.In vivo syngeneic tumour models were implanted subcutaneously into Balb/c (CT26) or C57/Bl6 (MC38) mice and treated with adavosertib or anti-murine PD-L1 at the indicated doses and schedules. This evidence concerns the gene CD274 and neoplasm.